money moves

Houston software startup raises $12.5M series B

Codenotary's software enables tools for notarization and verification of the software development life cycle. Photo via Getty Images

Houston-based Codenotary, whose technology helps secure software supply chains, has raised $12.5 million in a series B round. Investors in the round include Swiss venture capital firm Bluwat and French venture capital firm Elaia.

The $12.5 million round follows a series A round that was announced in 2020, with total funding now at $18 million.

Codenotary, formely known as vChain, says the fresh round of money will be used to accelerate product development, and expand marketing and sales worldwide. Today, the startup has 100-plus customers, including some of the world’s largest banks.

Codenotary’s co-founders are CEO Moshe Bar and CTO Dennis Zimmer. They started the company in 2018.

Bar co-founded Qumranet, which developed the Linux KVM hypervisor. A hypervisor creates and runs virtual machines. Software provider Red Hat purchased Qumranet in 2008 for $127 million. Before that, he founded hypervisor company XenSource, which cloud computing company Citrix Systems bought in 2007 for $500 million.

“Codenotary offers a solution which allows organizations to quickly identify and track all components in their DevOps cycle and therefore restore trust and integrity in all their myriad applications,” Pascal Blum, senior partner at Bluwat, says in a news release.

The SolarWinds software supply chain hack in 2020 and the more recent emergence of Log4j vulnerabilities have brought the dangers of software lifecycle attacks to the forefront, Bar says. Now, he says, more and more companies are looking for ways to prove the legitimacy of the software that they produce.

Codenotary is the primary contributor to immudb, the an open-source, enterprise-class database with data immutability, or stability, designed to meet the demands of highly used applications.

Trending News

Building Houston

 
 

Houston-based Melax Tech has developed multiple Natural language processing tools that are used by more than 650 health care and life science organizations. Photo via MelaxTech.com

Melax Tech Partners, a leader in natural language technology processing, announced a new partnership with the University of California at Irvine that will help researchers derive insights from the UCI Health Data Science Platform’s electronic health records system and improve patient care.

Melax will implement its signature text annotation tool LANN to pull information from clinical notes, and its CLAMP product to develop natural language processing customizations through the use of AI, according to a statement from the company.

“There has been a strong desire among UCI researchers to have the capability to analyze free-text clinical narrative data using cutting-edge NLP technologies," Kai Zheng, chief research information officer at UCI Health Affairs, says in a statement. "We are delighted to have this opportunity to work with Melax Tech to deploy their AI-driven annotation and analytics tools to help our researchers advance their research agenda by leveraging the vast amount of free-text data that our health system has accumulated in the past two decades.”

Natural language processing, or NLP, allows organizations and healthcare groups to sift through and analyze massive amounts of data at a rapid rate through the use of machine learning and AI. Houston-based Melax Tech, founded in 2017, has developed multiple NLP tools that are used by more than 650 health care and life science organizations, according to its website.

In addition to the recent partnership with UC Irvine, Melax has also recently partnered with Vanderbilt University Medical Center and the University of Western Pennsylvania on similar clinical projects.

Melax has also used its platforms to pull vital information from datasets relating to COVID-19, in both medical and social settings.

In March 2022, it was awarded a Phase 1 NIH Award, valued at $300,000, to develop informatics tools based on COVID-19 datasets with the San Diego Supercomputer Center at UC San Diego. The tool aims to help researchers better understand vast amounts of virus-related data and connect findings with other similar results.

In August, Melax also received another $300,000 grant from the National Institute of Allergy and Infectious Diseases to develop NLP-based algorithms that will "model, extract and synthesize vaccine misinformation from multiple popular social media sources," according to a statement. Melax will also develop a visualization that presents its findings on the misinformation into a compressible format.

"This is a very real topic affecting culture at present," Andre Pontin, CEO at Melax Tech, says in a statement. "And shows that we as a collective business and group of experts continue to be on the cutting-edge of science in the NLP and AI domain."

Trending News